$STIM earnings report

Neuronetics reported third-quarter total revenue growth of 12.5%, positive income from operations of $0.5 million, adjusted EBITDA of $1.9 million, and reaffirmed full-year revenue guidance. AlphAI read Neuronetics's third quarter of 2026 filing as solid. 2 quarters are on record below.

third quarter of 2026

AlphAI · Earnings readSTIM · third quarter of 2026 · ended September 30, 2026

Neuronetics reported third-quarter total revenue growth of 12.5%, positive income from operations of $0.5 million, adjusted EBITDA of $1.9 million, and reaffirmed full-year revenue guidance.

✓Solid quarter

Greenbrook revenue grew 20.1%, gross margin expanded to 52.2%, operating expenses declined 13%, and the company delivered positive income from operations and adjusted EBITDA. NeuroStar revenue growth was 1.8%, cash declined from December 31, 2025, and full-year operating and investing cash flow guidance remains negative.

Revenue
$42.0M
12.5% y/y
NeuroStar revenue, three months ended September 30, 2026
$15.8M
1.8% y/y
Gross margin · GAAP
52.2%
EPS · GAAP
$(0.02)
full year 2026 outlook
$160 million to $164 million
GM 49% to 50%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026 (in thousands)GAAP$41.96M–12.5%
Total cost of revenues, three months ended September 30, 2026 (in thousands)GAAP$20.07M––
Gross profit, three months ended September 30, 2026 (in thousands)GAAP$21.89M––
Gross margin, three months ended September 30, 2026GAAP52.2%––
Sales and marketing expense, three months ended September 30, 2026 (in thousands)GAAP$8.48M––
General and administrative expense, three months ended September 30, 2026 (in thousands)GAAP$11.68M––
Research and development expense, three months ended September 30, 2026 (in thousands)GAAP$1.19M––
Total operating expenses, three months ended September 30, 2026 (in thousands)GAAP$21.35M–decrease of $3.1 million, or 13%
Income (Loss) from operations, three months ended September 30, 2026 (in thousands)GAAP$541K–increase of $7.9 million
Interest expense, three months ended September 30, 2026 (in thousands)GAAP$2.14M––
Other income, net, three months ended September 30, 2026 (in thousands)GAAP−$47K––
Net loss, three months ended September 30, 2026 (in thousands)GAAP−$1.56M––
Net loss attributable to Neuronetics stockholders, three months ended September 30, 2026 (in thousands)GAAP−$1.69M––
Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders, three months ended September 30, 2026GAAP$(0.02)––
Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026 (in thousands)GAAP77.00M––
EBITDA, three months ended September 30, 2026 (in thousands)non-GAAP$1.15M––
Adjusted EBITDA, three months ended September 30, 2026 (in thousands)non-GAAP$1.89M–increase of $6.6 million
Cash provided by operating and investing, third quarter of 2026other$800K––
Total revenues, nine months ended September 30, 2026 (in thousands)GAAP$118.0M––
Gross profit, nine months ended September 30, 2026 (in thousands)GAAP$59.27M––
Total operating expenses, nine months ended September 30, 2026 (in thousands)GAAP$69.22M––
Loss from operations, nine months ended September 30, 2026 (in thousands)GAAP−$9.96M––
Net loss attributable to Neuronetics stockholders, nine months ended September 30, 2026 (in thousands)GAAP−$15.92M––
Net loss per share of common stock outstanding, basic and diluted attributable to Neuronetics stockholders, nine months ended September 30, 2026GAAP$(0.22)––
Adjusted EBITDA, nine months ended September 30, 2026 (in thousands)non-GAAP−$4.44M––

Segments

SegmentRevenueq/qy/y
NeuroStar revenue, three months ended September 30, 2026The Company said it delivered a record third quarter within NeuroStar system sales and cited positive reception of expanded NeuroStar go-to-market options.$15.77M–1.8%
Greenbrook revenue, three months ended September 30, 2026The increase reflected continued growth of the Greenbrook business. The Company also cited revenue cycle management advances.$26.19M–20.1%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

full year 2026 outlook

  • Revenue$160 million to $164 million
  • Gross margin49% to 50%
  • Operating expensesOperating expenses between $92.5 million and $95.5 million; operating expenses, less stock-based compensation, between $89 million and $92 million; estimated stock-based compensation of $3.5 million.
  • NoteCash flow from operating and investing in the range of $(10.0) million to $(12.0) million.

What drove it

  • Higher Greenbrook revenue was the primary driver of total revenue growth.
  • Gross-margin expansion was primarily driven by the positive impact of the new go-to-market strategy and improved revenue cycle management within Greenbrook clinics.
  • Lower sales and marketing expenses drove the reduction in operating expenses, partly offset by higher general and administrative expenses.
  • The Company submitted a 510(k) application for an accelerated TMS protocol in August.
  • The Company signed a distribution agreement with Wave Neuro and plans to seek FDA clearance to add NeuroStar as a TMS system compatible with Wave Neuro's PTSD indication.
  • TrakStar integration with AdvancedMD is expected to become available to existing NeuroStar providers using AdvancedMD in the fourth quarter of 2026.

Concerns

  • NeuroStar revenue increased 1.8% year-over-year, compared with Greenbrook revenue growth of 20.1%.
  • Net loss attributable to Neuronetics stockholders was $(1,692) (in thousands) in the third quarter of 2026.
  • Long-term debt, net, was $61,752 (in thousands) as of September 30, 2026.
  • The full-year 2026 outlook calls for cash flow from operating and investing of $(10.0) million to $(12.0) million.
  • Accelerated TMS and PTSD opportunities are dependent on FDA review or clearance.

What to watch

  • Performance against full-year total revenue guidance of $160 million to $164 million.
  • Progress toward the full-year gross margin outlook of 49% to 50%.
  • Delivery of operating expenses between $92.5 million and $95.5 million and cash flow from operating and investing of $(10.0) million to $(12.0) million.
  • Availability of the AdvancedMD integration in the fourth quarter of 2026.
  • FDA review of the accelerated TMS 510(k) application and the planned FDA clearance effort for the Wave Neuro PTSD indication.

Balance sheet and cash flow

  • Total cash as of September 30, 2026 was $27.9 million, consisting of cash and cash equivalents of $22.1 million and $5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.
  • Cash and cash equivalents and restricted cash and cash equivalents at September 30, 2026 were $27,856 (in thousands), compared to $34,471 (in thousands) at September 30, 2025.
  • Long-term debt, net, was $61,752 (in thousands) as of September 30, 2026, compared to $65,807 (in thousands) as of December 31, 2025.
  • Net cash used in operating activities for the nine months ended September 30, 2026 was $(9,191) (in thousands), compared to $(21,282) (in thousands) for the nine months ended September 30, 2025.
  • Net cash used in investing activities for the nine months ended September 30, 2026 was $(1,059) (in thousands), compared to $(585) (in thousands) for the nine months ended September 30, 2025.
  • Net cash provided by financing activities for the nine months ended September 30, 2026 was $3,972 (in thousands), compared to $36,879 (in thousands) for the nine months ended September 30, 2025.
  • Proceeds from issuance of common stock under the ATM Program were $8,577 (in thousands) for the nine months ended September 30, 2026.

Analysis

Neuronetics delivered $41,962 thousand of total revenue in the third quarter of 2026, compared with $37,297 thousand in the third quarter of 2025. Greenbrook produced $26,192 thousand of revenue and grew 20.1%, while NeuroStar revenue was $15,770 thousand and grew 1.8%. The release identifies continued Greenbrook business growth as the principal revenue driver and describes record third-quarter performance in Greenbrook and NeuroStar system sales.

The operating model improved materially. Gross margin increased to 52.2% from 45.9%, which the Company attributed to its new go-to-market strategy and improved Greenbrook revenue cycle management. Total operating expenses declined to $21,349 thousand from $24,429 thousand, led by lower sales and marketing expense. Income from operations was $541 thousand, compared with a loss from operations of $(7,321) thousand, and adjusted EBITDA was $1,887 thousand, compared with $(4,670) thousand.

Below operating income, interest expense was $2,144 thousand and net loss attributable to Neuronetics stockholders was $(1,692) thousand, or $(0.02) per basic and diluted share. For the nine months ended September 30, 2026, net cash used in operating activities was $(9,191) thousand and net cash used in investing activities was $(1,059) thousand. Total cash at September 30, 2026 was $27.9 million, while long-term debt, net, was $61,752 thousand.

The full-year revenue outlook remains $160 million to $164 million. The gross-margin outlook is 49% to 50%, compared with prior guidance of 48% to 50%, while operating expense and operating-and-investing cash-flow outlooks were reduced from the prior ranges stated in the release. Operationally, the Company has an accelerated TMS 510(k) under review, plans to seek clearance for NeuroStar compatibility with Wave Neuro's PTSD indication, and expects its AdvancedMD integration to become available to existing NeuroStar providers using AdvancedMD in the fourth quarter of 2026.

Management, verbatim

This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation.

Dan Reuvers, President and Chief Executive Officer of Neuronetics

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported third-quarter operating metrics.
  • Quarterly operating cash flow and quarterly investing cash flow presented separately.
  • Free cash flow.
  • Dividends and share repurchases.
  • Income-tax rate.
  • Full-year adjusted EBITDA guidance.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readSTIM · Second Quarter 2026 · ended June 30, 2026

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

✓Solid quarter

Total revenue increased 9.1%, Greenbrook revenue increased 16.8%, gross margin expanded to 51.1%, operating expenses declined 12%, and Adjusted EBITDA improved to $0.3 million from a loss of $5.6 million. NeuroStar revenue declined 2.7%, the company remained loss-making, and total cash was lower than at December 31, 2025.

Revenue
$41.6M
9.1% y/y
NeuroStar revenue
$14.7M
(2.7 )% y/y
Gross margin · GAAP
51.1%
EPS · GAAP
$0.05
full year 2026 outlook
$160 million and $164 million
GM 48% and 50%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$41.6M–9.1%
Gross marginGAAP51.1%––
Operating expensesGAAP$22.7M–12%
Loss from operationsGAAP$1.5M–decrease of $6.6 million
Adjusted EBITDAnon-GAAP$300K–increase of $5.9 million
Net lossGAAP$3.4M––
Net loss per shareGAAP$0.05 per share––
Weighted average common shares outstandingGAAP73,129,107––
Net cash used in operations and investingother$1.4M–reduction of $2.3 million
Total cashother$25M––
Cash and cash equivalentsother$19.2M––
Restricted cashother$5.8M––

Segments

SegmentRevenueq/qy/y
NeuroStar revenueThe company said it is broadening how customers can access its technology through expanded NeuroStar go-to-market models.$14.68M–(2.7 )%
Greenbrook revenueThe increase reflected continued growth of the Greenbrook business.$26.89M–16.8 %

full year 2026 outlook

  • Revenue$160 million and $164 million
  • Gross margin48% and 50%
  • Operating expenses$95 million to $100 million
  • NoteOperating expenses, less SBC: $91 million to $96 million
  • NoteEstimated stock-based compensation: $4 million
  • NoteCash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million

What drove it

  • Total revenue growth was primarily driven by higher Greenbrook revenue.
  • Gross-margin expansion was driven by the positive impact of the new go-to-market strategy and improved revenue cycle management within the Greenbrook clinics.
  • Operating-expense reduction was primarily attributable to lower general and administrative expenses and lower sales and marketing expenses.
  • The company strengthened leadership with the appointment of Nir Naor as Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer; the promotion of Cory Anderson to Executive Vice President and General Manager of Greenbrook; and the appointment of Rob Greene as Senior Vice President, Sales.

Concerns

  • NeuroStar revenue declined (2.7 )% year over year.
  • The company reported a net loss of $3.4 million and a loss from operations of $1.5 million.
  • Total cash was $25 million as of June 30, 2026, compared to total cash of $34.1 million as of December 31, 2025.
  • Full-year 2026 guidance calls for cash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million.

What to watch

  • Execution of expanded NeuroStar go-to-market models and whether NeuroStar revenue returns to growth.
  • Continued Greenbrook revenue growth and revenue-cycle-management improvements within the clinics.
  • Sustainability of gross margin in the guided range of 48% and 50%.
  • Progress toward the company's goal of sustained profitability and positive net cash flow from operations and investing.
  • Operating-expense delivery against the $95 million to $100 million full-year guidance range.

Balance sheet and cash flow

  • As of June 30, 2026, the Company held $25 million in total cash, consisting of cash and cash equivalents of $19.2 million and $5.8 million of restricted cash, compared to total cash of $34.1 million as of December 31, 2025.
  • Net cash used in operations and investing of $1.4 million, a reduction of $2.3 million compared to $3.8 million in the second quarter of 2025.

Analysis

Neuronetics delivered year-over-year revenue growth in the second quarter, with total revenue of $41.6 million, up 9.1% from $38.1 million. The growth was driven by Greenbrook revenue of $26.9 million, up 16.8%, while NeuroStar revenue was $14.7 million and declined 2.7%. The segment mix makes Greenbrook the documented source of growth, while the NeuroStar decline remains the principal demand issue identified in the reported segment results.

Profitability improved materially. Gross margin increased to 51.1% from 46.6%, which the company attributed to its new go-to-market strategy and improved revenue cycle management in Greenbrook clinics. Operating expenses declined to $22.7 million from $25.8 million, primarily due to lower general and administrative expense and lower sales and marketing expense. Those changes reduced loss from operations to $1.5 million from a loss of $8.1 million and brought Adjusted EBITDA to $0.3 million from a loss of $5.6 million.

The company remained unprofitable on a GAAP basis, reporting a net loss of $3.4 million, or $0.05 per share, compared with a net loss of $10.1 million, or $0.15 per share. Net cash used in operations and investing was $1.4 million, compared to $3.8 million in the second quarter of 2025. Total cash was $25 million as of June 30, 2026, compared with $34.1 million as of December 31, 2025, and consisted of $19.2 million in cash and cash equivalents and $5.8 million in restricted cash.

For full-year 2026, the company expects total revenue between $160 million and $164 million, gross margin between 48% and 50%, and operating expenses between $95 million to $100 million. It also expects operating expenses less stock-based compensation of $91 million to $96 million, with estimated stock-based compensation of $4 million. The company expects cash flow from operations and investing in the range of negative $10.5 million to negative $14.5 million. The release contains no first-quarter 2026 figures, so it does not support a documented sequential comparison.

The key operating focus is whether the new NeuroStar access and go-to-market models can reverse the reported revenue decline while Greenbrook continues to grow. Investors should also focus on the durability of the gross-margin improvement, execution against the reduced operating-expense outlook, and cash use against the full-year cash-flow guidance. Leadership changes place finance, Greenbrook clinic operations, and NeuroStar sales under newly appointed or promoted executives during this execution period.

Management, verbatim

This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operations and investing.

Dan Reuvers, President and Chief Executive Officer of Neuronetics

For some time, NeuroStar has not competed to its full potential, and we are changing that by broadening how customers can access our technology while we continue to drive operational gains across the Greenbrook clinics.

Dan Reuvers, President and Chief Executive Officer of Neuronetics

Not in the filing

stated, not guessed
  • Prior-quarter revenue, segment revenue, gross margin, operating expenses, operating income or loss, net income or loss, EPS, Adjusted EBITDA, and cash-flow comparisons were not reported.
  • Gross profit was not reported.
  • GAAP operating income was not reported; the company reported loss from operations.
  • Non-GAAP net income or loss and non-GAAP EPS were not reported.
  • Operating cash flow and investing cash flow as separate line items were not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Tax rate was not reported.
  • A prior quarterly outlook document was not provided, so no reported actual-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about STIM earnings dates

When is Neuronetics's next earnings date?
AlphAI has no date for STIM yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.